4SC Gives Update on the Clinical Development of its Lead Cancer ...
4SC AG announced positive Phase I results for resminostat combined with FOLFIRI in advanced CRC, showing safety, tolerability, and clinical activity. Encouraging biomarker data from Phase II trials in HCC and HL suggest ZFP64 gene expression as a potential biomarker for resminostat treatment outcomes. 4SC plans further development and discussions with partners and regulators.
Reference News
4SC AG announced positive Phase I results for resminostat combined with FOLFIRI in advanced CRC, showing safety, tolerability, and clinical activity. Encouraging biomarker data from Phase II trials in HCC and HL suggest ZFP64 gene expression as a potential biomarker for resminostat treatment outcomes. 4SC plans further development and discussions with partners and regulators.